Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Table 1

Basic characteristics of literature research.

Study ID	Sample size		Age (year)		Duration	Follow-up time	Intervention	Control	SBP dosage	Outcomes
	T	C	T	C
Sun, [14]	64	64	72.55 ± 3.63	72.34 ± 3.46	6 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	①
Huang, [15]	30	30	56.81 ± 12.61	55.11 ± 12.32	12 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	④
Xu, [16]	100	100	59.76 ± 10.43	59.36 ± 10.13	3 months	12 months	SBP + control	PCI + CT	1 pill, t.i.d.	①④⑤⑥
Feng, [17]	45	45	62.8 ± 5.1	62.5 ± 4.8	1 month	12 months	SBP + control	PCI + CT	3 pills, t.i.d.	①④⑤
Si, [18]	60	60	50.13 ± 11.27 (total)		6 months	18 months	SBP + control	PCI + CT	2 pills, t.i.d.	①④⑤
Jia, [19]	37	35	55.00 ± 10.73	60.31 ± 11.67	6 months	6 months	SBP + control	PCI + CT	2 pills, t.i.d.	③
Hu, [20]	50	50	58.0 ± 8.7(total)		12 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	①
Gao, [21]	51	51	NR		12 months	12 months	SBP + control	PCI + CT	2 pills, t.i.d.	①②
Zhang, [22]	60	50	48.10 ± 5.12	48.15 ± 5.10	6 months	NR	SBP + control	PCI + CT	2 pills, b.i.d.	①④
Song, [23]	50	50	56.4 ± 8.6	55.9 ± 7.7	3 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	①②③⑥
Yu, [24]	60	60	62.41 ± 4.33	62.53 ± 4.42	1 month	NR	SBP + control	PCI + CT	2 pills, t.i.d.	②
Wei, [25]	36	36	65.25 ± 6.30	64.90 ± 6.16	3 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	②④
Ran, [26]	100	100	61.00 ± 10.33	62.31 ± 12.07	12 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	③⑤
Jia, [27]	38	38	61.3 ± 8.9	59.8 ± 9.1	2 months	NR	SBP + control	PCI + CT	3 pills, t.i.d.	①
Zhang, [28]	55	55	60.5 ± 9.1	61.7 ± 10.3	4 weeks	NR	SBP + control	PCI + CT	2 pills, t.i.d.	①②③⑥
Song, [29]	33	33	73.92 ± 8.11	73.29 ± 8.03	16 weeks	NR	SBP + control	PCI + CT	1 pill, t.i.d.	①②⑥
Shi, [30]	40	40	66.8 ± 6.9	68.2 ± 7.5	3 months	NR	SBP + control	PCI + CT	2 pills, t.i.d.	①②
Ma, [31]	60	56	62.17 ± 8.33	61.96 ± 7.45	4 weeks	3 months	SBP + control	PCI + CT	2 pills, t.i.d.	①②
Sun [32]	50	50	61 ± 3	61 ± 3	1 week	4 weeks	SBP + control	PCI + CT	2 pills, t.i.d.	①②

Notes: T, trial group; C, control group; NR, not report; SBP, Shexiang Baoxin Pill; PCI, percutaneous coronary intervention; CT, conventional treatment; t.i.d., three times a day; b.i.d., two times a day; ① MACE ② LVEF; ③ NT-pro-BNP; ④ inflammatory mediators; ⑤ blood lipid index; ⑥ adverse reactions.